Abeona Therapeutics Inc.
US ˙ NasdaqCM ˙ US00289Y2063

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark J Ahn. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark J Ahn has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ABEO / Abeona Therapeutics Inc. Director 150,000
US:GALE / Galena Biopharma, Inc. President & CEO, Director 116,225
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark J Ahn. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ABEO / Abeona Therapeutics Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ABEO / Abeona Therapeutics Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2015-07-31 ABEO Ahn Mark J 18,182 5.5000 727 137.5000 100,001 4 6.8850 -94,996 -94.99
2015-01-26 PTBI Ahn Mark J 25,000 4.0000 1,000 100.0000 100,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ABEO / Abeona Therapeutics Inc. Insider Trades
Insider Sales ABEO / Abeona Therapeutics Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ABEO / Abeona Therapeutics Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ABEO / Abeona Therapeutics Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark J Ahn as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2016-12-15 2016-12-13 4 ABEO ABEONA THERAPEUTICS INC.
Stock option (right to buy)
A - Award 150,000 150,000
2016-11-09 2016-11-08 4 ABEO ABEONA THERAPEUTICS INC.
Stock option (right to buy)
M - Exercise 150,000 0 -100.00 2.31 346,500
2016-11-09 2016-11-08 4 ABEO ABEONA THERAPEUTICS INC.
Common stock
M - Exercise 150,000 493,182 43.71 2.31 346,500 1,139,250
2016-02-16 2016-02-11 4 ABEO ABEONA THERAPEUTICS INC.
Stock option (right to buy)
A - Award 150,000 150,000
2015-08-03 2015-07-31 4 ABEO ABEONA THERAPEUTICS INC.
Common stock
P - Purchase 18,182 343,182 5.59 5.50 100,001 1,887,501
2015-06-19 2015-05-11 4/A ABEO ABEONA THERAPEUTICS INC.
Stock option (right to buy)
A - Award 100,000 100,000
2015-06-19 2015-05-11 4/A ABEO ABEONA THERAPEUTICS INC.
Common stock
A - Award 300,000 325,000 1,200.00
2015-05-13 2015-05-11 4 PTBI PLASMATECH BIOPHARMACEUTICALS INC
Stock option (right to buy)
A - Award 100,000 115,320 652.74 7.34 734,000 846,449
2015-05-13 2015-05-11 4 PTBI PLASMATECH BIOPHARMACEUTICALS INC
Common stock
A - Award 300,000 325,000 1,200.00 7.34 2,202,000 2,385,500
2015-01-26 2015-01-26 4 PTBI PLASMATECH BIOPHARMACEUTICALS INC
Common Stock Purchase Warrants
P - Purchase 25,000 25,000 0.01 250 250
2015-01-26 2015-01-26 4 PTBI PLASMATECH BIOPHARMACEUTICALS INC
Common Stock
P - Purchase 25,000 25,000 4.00 100,000 100,000
2014-09-19 2014-06-30 4/A GALE Galena Biopharma, Inc.
Common Stock
A - Award 2,461 116,225 2.16 2.60 6,399 302,185
2014-07-02 2014-06-30 4 GALE Galena Biopharma, Inc.
Common Stock
J - Other 2,461 116,225 2.16 2.60 6,399 302,185
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Stock Option
M - Exercise -121,875 423,173 -22.36
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Stock Option
M - Exercise -200,000 200,000 -50.00
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Stock Option
M - Exercise -324,890 25,110 -92.83
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Stock Option
M - Exercise -100,000 0 -100.00
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Stock Option
M - Exercise -50,000 0 -100.00
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Common Stock
S - Sale -796,765 113,764 -87.51 4.83 -3,848,375 549,480
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 121,875 918,529 15.30 1.71 208,406 1,570,685
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 200,000 788,654 33.98 0.72 144,000 567,831
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 324,890 588,654 123.17 1.38 448,348 812,343
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 100,000 263,764 61.06 1.38 138,000 363,994
2014-01-29 2014-01-27 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 50,000 163,764 43.95 2.31 115,500 378,295
2014-01-29 2013-11-26 4/A GALE Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 600,000 600,000
2014-01-22 2013-12-31 4 GALE Galena Biopharma, Inc.
Common Stock
J - Other 5,656 113,764 5.23 1.88 10,625 213,706
2013-11-27 2013-11-26 4 gale Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 200,000 200,000
2013-11-27 2013-11-26 4 gale Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 600,000 600,000
2013-07-03 2013-06-30 4 GALE Galena Biopharma, Inc.
Common Stock, par value $0.0001
J - Other 7,862 108,108 7.84 1.35 10,614 145,946
2013-01-31 2013-01-29 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 650,000 650,000
2013-01-31 2012-12-31 4 GALE Galena Biopharma, Inc.
Common Stock, par value $0.0001
J - Other 7,668 100,246 8.28 1.30 9,968 130,320
2012-07-11 2012-07-10 4 GALE Galena Biopharma, Inc.
Common Stock, par value $0.0001
J - Other 31,289 92,578 51.05 0.40 12,500 36,985
2012-01-17 2012-01-12 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 400,000 400,000
2012-01-06 2011-12-31 4 GALE Galena Biopharma, Inc.
Common Stock, par value $.0001
J - Other 31,289 61,289 104.30 0.40 12,516 24,516
2011-04-21 2011-03-31 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 525,000 525,000
2011-04-21 2011-03-31 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 100,000 100,000
2011-04-20 2011-04-20 4 RXII RXI PHARMACEUTICALS CORP
Common Stock, par value $.0001
P - Purchase 10,000 10,000 0.95 9,500 9,500
2011-01-14 2011-01-13 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 50,000
2010-01-19 2010-01-14 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 50,000
2009-01-20 2009-01-15 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 150,000 50.00
2008-04-22 2008-04-18 4 RXII RXI PHARMACEUTICALS CORP
Non-Qualified Stock Option (right to buy)
A - Award 25,000 25,000
2008-02-14 3 NONE RXI PHARMACEUTICALS CORP
Common Stock
10,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)